Circulating Tumour DNA (ctDNA) as an Emerging Biomarker of Response in Early-Phase Oncology Drug Development: A Systematic Review
Targeted Oncology · 10.11.2026
DOI: 10.1007/s11523-026-01269-2 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Targeted Oncology, online erschienen am 10.11.2026. Verfasst von Nadav Harel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, VIC, Australia. nadav.harel@petermac.org. Die Arbeit nennt 75 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Circulating tumour DNA (ctDNA) analysis is increasingly integrated into early-phase oncology trials. However, its role as a pharmacodynamic biomarker of treatment response, particularly its association with radiological response, remains unclear. OBJECTIVE: We aimed to systematically evaluate the association between longitudinal ctDNA kinetics and radiological response according to Response Evaluation Criteria for Solid Tumors (RECIST) Version 1.1 in early-phase oncology trials. METHODS: A systematic literature search identified early-phase trials published from 2015 onwards that assessed correlations between ctDNA changes and RECIST radiological outcomes in adults receiving investigational anti-cancer therapy for solid tumours. RESULTS: Thirty-five studies were included, comprising 2962 treated patients. Significant heterogeneity was observed in ctDNA methodology between trials. Across studies, changes in longitudinal ctDNA were largely aligned with RECIST radiological outcomes. Across 18 cohorts with reconstructable 2 × 2 tables, molecular response was strongly associated with RECIST response (unadjusted odds ratio 7.24; 95% confidence interval 4.87-10.76). However, discordant responses between ctDNA dynamics and radiological outcomes were observed, highlighting the complexity of interpreting ctDNA changes during treatment. CONCLUSIONS: Longitudinal ctDNA monitoring in early-phase oncology trials demonstrates potential as a complementary pharmacodynamic biomarker of treatment response. Its broad, yet incomplete alignment with conventional efficacy outcomes suggests that ctDNA may provide early biological signal of treatment activity that may help predict clinical benefit. Significant methodological heterogeneity was observed. Future studies should prioritise methodological standardisation and prospective validation of ctDNA kinetics with efficacy outcomes. PROSPERO REGISTRATION: CRD420251064392.
Autor:innen und Institutionen
- Department of Medical Oncology, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, VIC, Australia. nadav.harel@petermac.org.
- Department of Medical Oncology, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, VIC, Australia.
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.
- The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
- Auckland City Hospital, Auckland, New Zealand.
- Cabrini Health, Melbourne, Victoria, Australia.
Zitieren
APA
Harel, N., Hamilton, A., Cope, T. C. T., Harris, W., Lefkovits, Y., Middleton, M., Desai, J., & Tie, J. (2026). Circulating Tumour DNA (ctDNA) as an Emerging Biomarker of Response in Early-Phase Oncology Drug Development: A Systematic Review. Targeted Oncology. https://doi.org/10.1007/s11523-026-01269-2
Vancouver
Harel N, Hamilton A, Cope TCT, Harris W, Lefkovits Y, Middleton M, et al. Circulating Tumour DNA (ctDNA) as an Emerging Biomarker of Response in Early-Phase Oncology Drug Development: A Systematic Review. Targeted Oncology. 2026. doi:10.1007/s11523-026-01269-2
BibTeX
@article{Harel2026,
author = {Harel, Nadav and Hamilton, Anthony and Cope, Thomas C T and Harris, William and Lefkovits, Yael and Middleton, Mark and Desai, Jayesh and Tie, Jeanne},
title = {Circulating Tumour DNA (ctDNA) as an Emerging Biomarker of Response in Early-Phase Oncology Drug Development: A Systematic Review},
journal = {Targeted Oncology},
year = {2026},
doi = {10.1007/s11523-026-01269-2}
}
EUVIMED